Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Voriconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 11/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | CYP3A7 | P24462 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 1.00 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Voriconazole SCHEMBL29449338 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL28720611 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL29449336 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL824156 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL1554444 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL29378592 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL29449335 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL371715 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL3949267 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL3713297 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190735-A1 | COMPOSITIONS COMPRISING VORICONAZOLE INHALATION POWDER AND METHODS OF MANUFACTURE AND USE THEREOF | CANVAS PHARMACEUTICALS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230190735-A1 | COMPOSITIONS COMPRISING VORICONAZOLE INHALATION POWDER AND METHODS OF MANUFACTURE AND USE THEREOF | CANVAS PHARMACEUTICALS, INC. | 2023-06-22 | — | — | US | disclosed |
| CN-111700864-B | Preparation method of voriconazole for injection | 海南倍特药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| US-20220213073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-07 | — | — | US | disclosed |
| EP-4019509-A1 | METHOD FOR PREPARING VORICONAZOLE L-CAMPHORSULPHONATE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| CN-114624369-A | Method for detecting voriconazole in sclera | 益诺思生物技术南通有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114577957-A | Detection method of voriconazole drug in iris | 益诺思生物技术南通有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11312707-B2 | Compositions and methods for the treatment of fungal infections | CELLIX BIO PRIVATE LIMITED (IN) | 2022-04-26 | — | — | US | disclosed |
| CN-114371242-A | Detection method of voriconazole drug in conjunctiva | 益诺思生物技术南通有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-2720723-B1 | STABILIZED VORICONAZOLE COMPOSITION | SYNTHON BV (NL) | 2018-04-11 | — | — | EP | disclosed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-9789108-B2 | Methods of colchicine administration | HIKMA PHARMACEUTICALS LLC (JO) | 2017-10-17 | — | — | US | disclosed |
| EP-1899327-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 2R, 3S-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL) BUTAN-2-OL (VORICONAZOLE) | MSN Laboratories Limited (IN) | 2008-03-19 | — | — | EP | disclosed |
| EP-1899327-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 2R, 3S-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL) BUTAN-2-OL (VORICONAZOLE) | MSN Laboratories Limited (IN) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007013096-A8 | IMPROVED PROCESS FOR THE PREPARATION OF 2R, 3S-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL) BUTAN-2-OL (VORICONAZOLE) | MSN LAB LTD (IN) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013096-A8 | IMPROVED PROCESS FOR THE PREPARATION OF 2R, 3S-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL) BUTAN-2-OL (VORICONAZOLE) | MSN LAB LTD (IN) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013096-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 2R, 3S-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL) BUTAN-2-OL (VORICONAZOLE) | MSN LABORATORIES LIMITED (IN) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007013096-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 2R, 3S-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL) BUTAN-2-OL (VORICONAZOLE) | MSN LABORATORIES LIMITED (IN) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | CYP3A4 385/4885CYP2C9 245/4885CYP2C19 131/4885 |
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | PKD2, PKD1, MUC1 | CYP3A4 2916/4885CYP2C9 2502/4885CYP2C19 2498/4885 |
| US-11312707-B2 | Compositions and methods for the treatment of fungal infections | SI, CYP3A7, ERG28 | CYP3A4 4/4885CYP2C9 31/4885CYP2C19 40/4885 |
| US-20230190735-A1 | COMPOSITIONS COMPRISING VORICONAZOLE INHALATION POWDER AND METHODS OF MANUFACTURE AND USE THEREOF | IL33, CYP3A43, WNK3 | CYP3A4 24/4885CYP2C9 73/4885CYP2C19 10/4885 |
| US-20220213073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | SI, CYP3A7, ERG28 | CYP3A4 4/4885CYP2C9 31/4885CYP2C19 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.